Display options
Cite
Tydings C, Kim A. Technology and precision therapy delivery in childhood cancer. Curr Opin Pediatr. 2020;32(1):1-6doi: 10.1097/MOP.0000000000000865.
Tydings, C., & Kim, A. (2020). Technology and precision therapy delivery in childhood cancer. Current opinion in pediatrics, 32(1), 1-6. https://doi.org/10.1097/MOP.0000000000000865
Tydings, Caitlin, and Kim, AeRang. "Technology and precision therapy delivery in childhood cancer." Current opinion in pediatrics vol. 32,1 (2020): 1-6. doi: https://doi.org/10.1097/MOP.0000000000000865
Tydings C, Kim A. Technology and precision therapy delivery in childhood cancer. Curr Opin Pediatr. 2020 Feb;32(1):1-6. doi: 10.1097/MOP.0000000000000865. PMID: 31876621.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Pediatr. 2020 Feb;32(1):1-6. doi: 10.1097/MOP.0000000000000865.

Technology and precision therapy delivery in childhood cancer.

Current opinion in pediatrics

Caitlin Tydings, AeRang Kim

Affiliations

  1. Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, District of Columbia, USA.

PMID: 31876621 DOI: 10.1097/MOP.0000000000000865

Abstract

PURPOSE OF REVIEW: The purpose of this review is to describe current advances in pediatric precision therapy through innovations in technology and engineering. A multimodal approach of chemotherapy, surgery and/or radiation therapy has improved survival outcomes for pediatric cancer but with significant early and late toxicities. The pediatric population is particularly vulnerable given their age during treatment. Advances in precision interventions discussed include image guidance, ablation techniques, radiation therapy and novel drug delivery mechanisms that offer the potential for more targeted approach approaches with improved efficacy while limiting acute and late toxicities.

RECENT FINDINGS: Image-guidance provides improved treatment planning, real time monitoring and targeting when combined with ablative techniques and radiation therapy. Advances in drug delivery including radioisotopes, nanoparticles and antibody drug conjugates have shown benefit in adult malignancies with increasing use in pediatrics. These therapies alone and combined may lead to augmented local antitumor effect while sparing systemic exposure and potentially limiting early and late toxicities.

SUMMARY: Pediatric cancer medicine often requires a multimodal approach, each with early and late toxicities. Precision interventions and therapies offer promise for more targeted approaches in treating pediatric malignancies and require further investigation to determine long-term benefit.

References

  1. Debes A, Willers R, Göbel U, Wessalowski R. Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy. Pediatr Blood Cancer 2005; 45:663–669. - PubMed
  2. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 2008; 30:425–430. - PubMed
  3. Ray A, Huh WW. Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas. Curr Oncol Rep 2012; 14:311–319. - PubMed
  4. Hoffer FA, Daw NC, Xiong X, et al. A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer 2009; 115:1328–1337. - PubMed
  5. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004; 22:300–306. - PubMed
  6. O’Neal D, Cohen T, Peterson C, Barr RG. Contrast-enhanced ultrasound-guided radiofrequency ablation of renal tumors. J Kidney Cancer VHL 2018; 5:7–14. - PubMed
  7. Sharma KV, Yarmolenko PS, Celik H, et al. Comparison of noninvasive high-intensity focused ultrasound with radiofrequency ablation of osteoid osteoma. J Pediatr 2017; 190:222–228.e1. - PubMed
  8. Earhart J, Wellman D, Donaldson J, et al. Radiofrequency ablation in the treatment of osteoid osteoma: results and complications. Pediatr Radiol 2013; 43:814–819. - PubMed
  9. Yevich S, Calandri M, Gravel G, et al. Reiterative radiofrequency ablation in the management of pediatric patients with hepatoblastoma metastases to the lung, liver, or bone. Cardiovasc Intervent Radiol 2019; 42:41–47. - PubMed
  10. Hinshaw JL, Lubner MG, Ziemlewicz TJ, et al. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics 2014; 34:1344–1362. - PubMed
  11. Baust JG, Gage AA, Bjerklund Johansen TE, et al. Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology 2014; 68:1–11. - PubMed
  12. Whitmore MJ, Hawkins CM, Prologo JD, et al. Cryoablation of osteoid osteoma in the pediatric and adolescent population. J Vasc Interv Radiol 2016; 27:232–237. quiz 238. - PubMed
  13. Wu B, Xiao YY, Zhang X, et al. CT-guided percutaneous cryoablation of osteoid osteoma in children: an initial study. Skeletal Radiol 2011; 40:1303–1310. - PubMed
  14. Schmitz JJ, Schmit GD, Atwell TD, et al. Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience. AJR Am J Roentgenol 2016; 207:190–195. - PubMed
  15. Redifer Tremblay K, Lea WB, Neilson JC, et al. Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J Surg Oncol 2019; 120:366–375. - PubMed
  16. Gomez FM, Patel PA, Stuart S, Roebuck DJ. Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children. Pediatr Radiol 2014; 44:1281–1289. - PubMed
  17. Seror O. Ablative therapies: advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient? Diagn Interv Imaging 2015; 96:617–624. - PubMed
  18. Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver 2010; 4: (Suppl 1): S113–S118. - PubMed
  19. Jolesz FA, Hynynen K, McDannold N, Tempany C. MR imaging-controlled focused ultrasound ablation: a noninvasive image-guided surgery. Magn Reson Imaging Clin N Am 2005; 13:545–560. - PubMed
  20. Napoli A, Bazzocchi A, Scipione R, et al. Noninvasive therapy for osteoid osteoma: a prospective developmental study with MR imaging-guided high-intensity focused ultrasound. Radiology 2017; 285:186–196. - PubMed
  21. Geiger D, Napoli A, Conchiglia A, et al. MR-guided focused ultrasound (MRgFUS) ablation for the treatment of nonspinal osteoid osteoma: a prospective multicenter evaluation. J Bone Joint Surg Am 2014; 96:743–751. - PubMed
  22. Ghanouni P, Dobrotwir A, Bazzocchi A, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol 2017; 27:732–740. - PubMed
  23. Kim YS. Advances in MR image-guided high-intensity focused ultrasound therapy. Int J Hyperthermia 2015; 31:225–232. - PubMed
  24. Shim J, Staruch RM, Koral K, et al. Pediatric sarcomas are targetable by MR-guided high intensity focused ultrasound (MR-HIFU): anatomical distribution and radiological characteristics. Pediatr Blood Cancer 2016; 63:1753–1760. - PubMed
  25. van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother 2017; 66:247–258. - PubMed
  26. Liu F, Hu Z, Qiu L, et al. Boosting high-intensity focused ultrasound-induced antitumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J Transl Med 2010; 8:7. - PubMed
  27. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 2007; 119:554–568. - PubMed
  28. Hu M, Jiang L, Cui X, et al. Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol 2018; 11:136. - PubMed
  29. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer 2005; 93:849–854. - PubMed
  30. Indelicato DJ, Bradley JA, Rotondo RL, et al. Outcomes following proton therapy for pediatric ependymoma. Acta Oncol 2018; 57:644–648. - PubMed
  31. Mokhtech M, Rotondo RL, Bradley JA, et al. Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors. Pediatr Blood Cancer 2018; 65:e26997. - PubMed
  32. Sato M, Gunther JR, Mahajan A, et al. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer 2017; 123:2570–2578. - PubMed
  33. Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 2016; 17:287–298. - PubMed
  34. Vogel J, Both S, Kirk M, et al. Proton therapy for pediatric head and neck malignancies. Pediatr Blood Cancer 2018; 65: doi: 10.1002/pbc.26858. Epub 2017 Oct 23. - PubMed
  35. Leiser D, Calaminus G, Malyapa R, et al. Tumour control and quality of life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy. Radiother Oncol 2016; 120:163–168. - PubMed
  36. Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2016; 63:1522–1526. - PubMed
  37. Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol 2017; 28:2179–2184. - PubMed
  38. Mizumoto M, Murayama S, Akimoto T, et al. Long-term follow-up after proton beam therapy for pediatric tumors: a Japanese national survey. Cancer Sci 2017; 108:444–447. - PubMed
  39. Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 2014; 120:126–133. - PubMed
  40. Fukushima H, Fukushima T, Suzuki R, et al. Comorbidity and quality of life in childhood cancer survivors treated with proton beam therapy. Pediatr Int 2017; 59:1039–1045. - PubMed
  41. Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol 2014; 113:89–94. - PubMed
  42. Ludmir EB, Grosshans DR, Woodhouse KD. Radiotherapy advances in pediatric neuro-oncology. Bioengineering (Basel) 2018; 5: pii: E97. doi: 10.3390/bioengineering5040097. - PubMed
  43. Brown LC, Lester RA, Grams MP, et al. Stereotactic body radiotherapy for metastatic and recurrent Ewing sarcoma and osteosarcoma. Sarcoma 2014; 2014:418270. - PubMed
  44. Marcus KJ, Goumnerova L, Billett AL, et al. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys 2005; 61:374–379. - PubMed
  45. Jadvar H. Targeted radionuclide therapy: an evolution toward precision cancer treatment. AJR Am J Roentgenol 2017; 209:277–288. - PubMed
  46. Agrawal A, Rangarajan V, Shah S, et al. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol 1091; 91:20180103. - PubMed
  47. Schmidt M, Baum RP, Simon T, Howman-Giles R. Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging 2010; 54:411–428. - PubMed
  48. Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol 2014; 804:291–304. - PubMed
  49. Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 2018; 19:1040–1050. - PubMed
  50. Basha R, Sabnis N, Heym K, et al. Targeted nanoparticles for pediatric leukemia therapy. Front Oncol 2014; 4:101. - PubMed
  51. Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002; 8:413–418. - PubMed
  52. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21:167–176. - PubMed
  53. Tak WY, Lin SM, Wang Y, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res 2018; 24:73–83. - PubMed
  54. Lyon PC, Gray MD, Mannaris C, et al. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol 2018; 19:1027–1039. - PubMed
  55. Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release 2012; 158:487–494. - PubMed
  56. Jones L, McCalmont H, Evans K, et al. Preclinical activity of the antibody–drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatr Blood Cancer 2019; 66:e27765. - PubMed
  57. Roth M, Barris DM, Piperdi S, et al. Targeting glycoprotein NMB with antibody-drug conjugate, glembatumumab vedotin, for the treatment of osteosarcoma. Pediatr Blood Cancer 2016; 63:32–38. - PubMed
  58. Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 2013; 19:1567–1576. - PubMed

MeSH terms

Publication Types